These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18682248)

  • 21. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
    Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
    Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
    Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
    J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry.
    Mzoughi O; Teixido M; Planès R; Serrero M; Hamimed I; Zurita E; Moreno M; Granados G; Lakhdar-Ghazal F; BenMohamed L; Giralt E; Bahraoui E
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31477581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
    Cai L; Pan C; Xu L; Shui Y; Liu K; Jiang S
    FASEB J; 2012 Mar; 26(3):1018-26. PubMed ID: 22085645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
    Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y
    J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
    J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.
    Kliger Y; Levanon EY
    BMC Microbiol; 2003 Sep; 3():20. PubMed ID: 14499001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
    Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
    J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B; Tian YS; Utachee P; Sapsutthipas S; Isarangkura-na-Ayuthaya P; Auwanit W; Takagi T; Ikuta K; Sawanpanyalert P; Kawashita N; Kameoka M
    Virology; 2010 Sep; 405(1):157-64. PubMed ID: 20580393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
    Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.
    Kliger Y; Gallo SA; Peisajovich SG; Munoz-Barroso I; Avkin S; Blumenthal R; Shai Y
    J Biol Chem; 2001 Jan; 276(2):1391-7. PubMed ID: 11027678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
    Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
    Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H; Qiu Z; Su Y; Yang L; He Y
    AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
    Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
    Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.
    Chong H; Qiu Z; Su Y; He Y
    J Med Chem; 2015 Aug; 58(16):6378-88. PubMed ID: 26256053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
    Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.